Ingalls & Snyder’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $1.1M | Buy |
29,042
+225
| +0.8% | +$10.4K | 0.03% | 220 |
|
|
2026
Q2 | $1.38M | Sell |
28,817
-75
| -0.3% | -$3.22K | 0.04% | 202 |
|
|
2026
Q1 | $1.06M | Sell |
28,892
-586
| -2% | -$27.8K | 0.04% | 214 |
|
|
2025
Q4 | $1.5M | Sell |
29,478
-17,246
| -37% | -$882K | 0.06% | 184 |
|
|
2025
Q3 | $2.59M | Sell |
46,724
-3,957
| -8% | -$232K | 0.08% | 144 |
|
|
2025
Q2 | $3.5M | Sell |
50,681
-1,130
| -2% | -$76.9K | 0.12% | 115 |
|
|
2025
Q1 | $3.6M | Sell |
51,811
-835
| -2% | -$69K | 0.12% | 107 |
|
|
2024
Q4 | $4.53M | Buy |
52,646
+961
| +2% | +$104K | 0.18% | 91 |
|
|
2024
Q3 | $6.15M | Buy |
51,685
+1,037
| +2% | +$138K | 0.24% | 75 |
|
|
2024
Q2 | $7.23M | Buy |
50,648
+19,839
| +64% | +$2.63M | 0.31% | 60 |
|
|
2024
Q1 | $3.96M | Sell |
30,809
-2,355
| -7% | -$280K | 0.17% | 97 |
|
|
2023
Q4 | $3.43M | Sell |
33,164
-1,775
| -5% | -$176K | 0.16% | 105 |
|
|
2023
Q3 | $3.18M | Buy |
34,939
+3
| +0% | +$264 | 0.15% | 101 |
|
|
2023
Q2 | $2.83M | Hold |
34,936
| – | – | 0.14% | 113 |
|
|
2023
Q1 | $2.78M | Hold |
34,936
| – | – | 0.14% | 105 |
|
|
2022
Q4 | $2.36M | Hold |
34,936
| – | – | 0.13% | 116 |
|
|
2022
Q3 | $1.74M | Hold |
34,936
| – | – | 0.1% | 141 |
|
|
2022
Q2 | $1.95M | Hold |
34,936
| – | – | 0.1% | 139 |
|
|
2022
Q1 | $1.94M | Hold |
34,936
| – | – | 0.09% | 155 |
|
|
2021
Q4 | $1.96M | Hold |
34,936
| – | – | 0.09% | 159 |
|
|
2021
Q3 | $1.68M | Sell |
34,936
-3,950
| -10% | -$191K | 0.08% | 179 |
|
|
2021
Q2 | $1.63M | Sell |
38,886
-50
| -0.1% | -$1.94K | 0.07% | 190 |
|
|
2021
Q1 | $1.31M | Hold |
38,936
| – | – | 0.06% | 205 |
|
|
2020
Q4 | $1.36M | Sell |
38,936
-2,000
| -5% | -$69.1K | 0.07% | 186 |
|
|
2020
Q3 | $1.42M | Sell |
40,936
-2,200
| -5% | -$73.3K | 0.1% | 149 |
|
|
2020
Q2 | $1.41M | Sell |
43,136
-1,500
| -3% | -$47.9K | 0.08% | 164 |
|
|
2020
Q1 | $1.34M | Hold |
44,636
| – | – | 0.09% | 156 |
|
|
2019
Q4 | $1.29M | Buy |
44,636
+7,130
| +19% | +$197K | 0.07% | 173 |
|
|
2019
Q3 | $970K | Sell |
37,506
-1,006
| -3% | -$25.4K | 0.05% | 223 |
|
|
2019
Q2 | $983K | Sell |
38,512
-9,780
| -20% | -$242K | 0.05% | 225 |
|
|
2019
Q1 | $1.26M | Sell |
48,292
-67,176
| -58% | -$1.65M | 0.06% | 193 |
|
|
2018
Q4 | $2.66M | Sell |
115,468
-58,384
| -34% | -$1.3M | 0.14% | 125 |
|
|
2018
Q3 | $4.1M | Buy |
+173,852
| New | +$4.24M | 0.17% | 109 |
|
Other funds holding NVO
Ingalls & Snyder's NVO Position: Q3 2026 in Review
Ingalls & Snyder increased its Novo Nordisk (NVO) stake by 0.78% in Q3 2026, buying an estimated $10.4K and bringing the position to 29,042 shares worth $1.1M. The position accounts for 0.03% of the portfolio, ranked #220.
Ingalls & Snyder first reported a position in NVO in Q3 2018 and has held it in 33 quarters since. The position peaked at $7.23M in Q2 2024. 1,061 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Ingalls & Snyder held 29,042 shares of Novo Nordisk worth $1.1M as of Q3 2026.
- Ingalls & Snyder bought 225 Novo Nordisk shares in Q3 2026, an estimated $10.4K.
- Novo Nordisk made up 0.03% of Ingalls & Snyder's portfolio in Q3 2026, its #220 holding.
- Ingalls & Snyder first reported a position in Novo Nordisk in Q3 2018 and has held it in 33 quarters since.
- Ingalls & Snyder's Novo Nordisk position peaked at $7.23M in Q2 2024.
- 1,061 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Ingalls & Snyder's 13F filing for Q3 2026, filed 12 Nov 2026.